Board Meeting24 Jul 2026, 01:48 pm
Dr. Lal PathLabs Approves Interim Dividend and Stock Options
AI Summary
Dr. Lal PathLabs Ltd's Board of Directors met on July 24, 2026, approving the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were granted under the Employee Restricted Stock Unit Plan 2025. The board also noted acquisitions approved by its wholly-owned subsidiaries: Dr Lal PathLabs FZCO, Dubai, approved a stake acquisition in Sunshine Healthcare Limited (Ghana), and Dr. Lal Ventures Private Limited approved a stake acquisition in Neuome Technologies Private Limited.
Key Highlights
- Approved un-audited financial results for Q1 FY27.
- Declared an interim dividend of ₹5 per share for FY27.
- Granted stock options to eligible employees.
- Noted subsidiary approvals for stake acquisitions in Ghana and India.
Price Impact
More from LALPATHLAB